Evidence map›Paper›PMID 35688334›Full record

ReviewSeminars in cancer biology2022

Extracellular vesicles in cancer therapy.

Shizhen Emily Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in cancer biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 62 citations in OpenAlex.

  1. Extracellular vesicles: Navigating new frontiers in glioblastoma therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Extracellular vesicles in spine tumors: biological roles, immune modulation, and therapeutic implications.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Shizhen Emily WangDepartment of Pathology, University of California, San Diego, CA 92093, USA. Electronic address: emilywang@ucsd.edu.
University of California San Diego · US

Funding

Role of breast cancer-secreted miRNA in directing a stromal metabolic plasticityR01CA218140 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WANG, SHIZHEN EMILY · 2017 to 2021
$2.4M
Targeting Chemotherapy-induced Breast Cancer StemnessR01CA206911 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WANG, SHIZHEN EMILY, YUAN, YUAN · 2017 to 2021
$2.3M
Role of breast cancer secreted miRNA in brain metastasisR01CA266486 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Shizhen Emily Wang · 2022 to 2026
$2.2M
NCI NIH HHS R01 CA206911NCI NIH HHS R01 CA218140NCI NIH HHS R01 CA266486
6 · The paper itself

Abstract

Extracellular vesicles (EVs), including a variety of membrane-enclosed nanosized particles carrying cell-derived cargo, mediate a major type of intercellular communication in physiological and pathological processes. Both cancer and non-cancer cells secrete EVs, which can travel to and influence various types of cells at the primary tumor site as well as in distant organs. Tumor-derived EVs contribute to cancer cell plasticity and resistance to therapy, adaptation of tumor microenvironment, local and systemic vascular remodeling, immunomodulation, and establishment of pre-metastatic niches. Therefore, targeting the production, uptake, and function of tumor-derived EVs has emerged as a new strategy for stand-alone or combinational therapy of cancer. On the other hand, as EV cargo partially reflects the genetic makeup and phenotypic properties of the secreting cell, EV-based biomarkers that can be detected in biofluids are being developed for cancer diagnosis and for predicting and monitoring tumor response to therapy. Meanwhile, EVs from presumably safe sources are being developed as delivery vehicles for anticancer therapeutic agents and as anticancer vaccines. Numerous reviews have discussed the biogenesis and characteristics of EVs and their functions in cancer. Here, I highlight recent advancements in translation of EV research outcome towards improved care of cancer, including developments of non-invasive EV-based biomarkers and therapeutic agents targeting tumor-derived EVs as well as engineering of therapeutic EVs.

Indexed as

Extracellular VesiclesNeoplasmsBiomarkersCell CommunicationHumansTumor MicroenvironmentBiomarkersAnticancer vaccinesCancer therapyDrug delivery vehiclesExosomesExtracellular vesiclesMetastasisPremetastatic nicheTumor microenvironment

Identifiers

PMID35688334
PMCPMC10431950
OpenAlexW4281666692

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.